XRME:XETRA:XETRA-Xtrackers MSCI USA ESG Screened UCITS ETF 2C EUR Hedged (EUR)

ETF | Others |

Last Closing

USD 8.965

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

724.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.46 (+0.92%)

USD 448.39B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.14 (+0.88%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.25 (+0.96%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.22 (+0.79%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.24 (+1.02%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

-0.64 (-0.42%)

USD 126.93B
JARI:XETRA Amundi Index Solutions - Amund..

+0.19 (+0.44%)

USD 102.57B
8R80:XETRA Amundi Index Solutions - Amund..

-0.04 (-0.03%)

USD 102.14B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.45 (+0.89%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.84 (+0.75%)

USD 80.38B

ETFs Containing XRME:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.51% 55% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.51% 55% F 56% F
Trailing 12 Months  
Capital Gain 23.21% 80% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.21% 80% B- 80% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 7.69% 68% D+ 66% D+
Dividend Return 7.69% 67% D+ 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.96% 58% F 66% D+
Risk Adjusted Return 70.15% 88% B+ 88% B+
Market Capitalization 0.14B 41% F 37% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.